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Non-cystic ﬁbrosis-related bronchiectasis is a chronic inﬂammatory lung disease, which is regarded as an “orphan” lung disease,
with little research devoted to the study of this condition. Bronchiectasis results in impaired quality of life and mortality if left
untreated. The tools available in the armamentarium for the management of bronchiectasis entail antibiotic therapy traditionally
used to treat exacerbations, stratagems to improve mucociliary clearance, and avoidance of toxins. Macrolides have been known
for the last two decades to have not only anti-bacterial eﬀects but immunomodulatory properties as well. In cystic ﬁbrosis, the use
of macrolides is well documented in subjects colonized with Pseudomonas aeruginosa, to improve quality of life and lung function.
There is currently emerging evidence to suggest the beneﬁt of macrolides in subjects not colonized with Pseudomonas aeruginosa.
This beneﬁcial eﬀect has been less explored in the context of bronchiectasis from other causes. The purpose of this paper is to
review the current literature on the use of macrolides in non-cystic ﬁbrosis related bronchiectasis in paediatrics.
1.Bronchiectasis
The term bronchiectasis is derived from the Greek words
bronkia (bronchial tubes), ek (out), and tasis (stretching).
The earliest description of bronchiectasis was by Laennac
in 1819 [1]. There are two anatomical classiﬁcation systems
used for the diagnosis of bronchiectasis, namely, the Reid
and Whitwell classiﬁcations [2, 3]. In the past few years, the
diagnostic criteria for bronchiectasis have changed, with the
diagnosis being based on the less invasive high-resolution
computerized tomography (HRCT). HRCT scanning has led
to easier diagnosis and follow up of bronchiectasis [4].
Theexactpathophysiologicalmechanismsforbronchiec-
tasis are unknown, with the currently accepted concept
being the “vicious cycle” theory proposed by Cole in the
mid-eighties (Figure 1)[ 5]. Cole’s theory evolves around an
initial “hit” or trigger that results in airway inﬂammation.
The inﬂammatory process is established such that, with
subsequent lung infections, persistent airway inﬂammation
occurs. This is associated with release of proinﬂammatory
cytokines interleukin-(IL-) 6, IL-8, and neutrophil elastases
[6–8]. These cytokines recruit inﬂammatory mediators,
whoseend-productismucousglandhypertrophyandmucus
hyperproduction. Excess mucus compromises the mucocil-
iary escalator, which further perpetuates microbial invasion
of the airway. Mucus performs an innate immune function
property in the lungs by acting as the ﬁrst barrier in
the airways. Mucus is made up of mucin proteins, water,
surfactant phospholipids, peptides, and defence proteins.
There are many changes that occur to the mucus prop-
erties of patients with chronic inﬂammatory lung disease
[9]. There is goblet cell hyperplasia, which contributes to
excessive mucus production. In the presence of infection
epithelial cells modulate the recruitment of inﬂammatory
cells by the production of chemokines, cytokines, adhesion
molecules, and modulation of expression of receptors. The
presenceofpersistentinfection,impairmentoftheprotective
mucociliary escalator, and the presence of enzymes such as
elastases cause damage to the airway and lung tissue [10].
Risk factors associated with bronchiectasis are over-
crowding, poverty, damp housing, macro- and micro-
malnutrition, indoor pollution with biomass fuels, and2 Mediators of Inﬂammation
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Figure 1: The pathophysiology of bronchiectasis the inﬂammatory
cycle as proposed by Cole.
environmental tobacco smoke. These risks factors have been
largely diminished in developing countries with rates of
bronchiectasis as low as 0.49 per 100000 population in
Finnishchildren[11–13].C ertaingr oupsindev elo pedc oun-
tries, such as the Alaskan natives of the Yokun Kuskokwim
Delta, the New Zealand Maori, and the Aborigines of Aus-
tralia, have inordinately high bronchiectasis rates, ranging
from 3.5 to 16 per 10000 [14–16]. This is in contradistinc-
tion to developing countries where there is a high infectious
disease burden and consequently high bronchiectasis rates
[17]. There is, however, no accurate prevalence data available
to quantify the problem in developing countries.
2. Immunology of Bronchiectasis
The innate immune system is activated by pathogen-asso-
ciated molecular patterns (PAMPs), which are recognized
by pattern recognition receptors such as toll-like receptors
(TLRs) [18, 19]. TLR activation triggers a cascade resulting
in the activation and nuclear translocation of nuclear factor
κβ (NFκβ) with subsequent release of proinﬂammatory
cytokines IL-1β,I L - 8 ,a n dT N F - α [20]. IL-8 is a potent
chemoattractant for neutrophils [21]. Neutrophils are inte-
gral to the innate immune mechanisms in the lung, with
neutrophillic inﬂammation being central in the pathogenesis
of bronchiectasis. Elevated levels of neutrophil derived prod-
ucts IL-6, IL-8 and TNF-α have been found in the sputum of
adults with stable bronchiectasis [22]. Transepithelial migra-
tion of neutrophils from the intravascular compartment
occurs in a coordinated fashion with interplay of various
adhesion molecules. Three families of adhesion molecules
mediatethis;theselectins,theintegrinsCD11/CD18,andthe
immunoglobulin superfamily that is, intravascular adhesion
molecule 1 (ICAM-1) and vascular adhesion molecule 1
(VCAM-1) [23]. These adhesion molecules are upregulated
in the presence of IL-1, TNF-α,a n dI L - 8 .B o t hV C A M - 1
and ICAM-1 have been found to be elevated in bronchiec-
tasis subjects [10]. Adherent neutrophils migrate to the
inﬂammatory site under the direction of the neutrophil
chemoattractant IL-8. Once activated, neutrophils produce
neutrophil elastase (NE) and matrix metalloproteinases:
MMP-8 and MMP-9. NE has three main mechanisms of
action. Firstly, it has proteolytic eﬀects from toxic products
that digest the airway elastin, basement membrane collagen,
and proteoglycan [23]. Secondly, it induces the release of
cytokines IL-6, IL-8, and GM-CSF [23]. Finally, it is a
powerful secretagogue inducing expression of mucin gene
MUC5AC via the generation of reactive oxygen species
[23]. In CF, the free elastase is associated with reduced
opsonizationofpathogens,thusactingasapotentstimulator
f o rI L - 8p r o d u c t i o n[ 24].
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a potent chemokine that allows prolonged
survival of neutrophils in the airway. The intensity of
the proinﬂammatory cytokines was also found to be
elevated in subjects with colonization of the airways by
microorganisms. This elevation in the cytokines, coupled
with the elevated proteases released from neutrophils,
namely, neutrophil elastase, MMP-2, MMP-6, and MMP-9,
overwhelms the antiprotease defence mechanisms rendering
the lung vulnerable to destruction [25–27]. The use of
antibiotics has been shown to result in a reduction of these
proinﬂammatory cytokines [28].
3. Management of Bronchiectasis
Interventions in the management of bronchiectasis include
medical as well as adjunctive therapies. The therapeutic goals
of management include the following: treatment of the
underlying disease, aggressive treatment of infections, pro-
motion of mucociliary clearance, promotion of normal
growth, avoidance of toxins, identiﬁcation and management
ofcomplications,andtreatmentofthechronicinﬂammation
to retard disease progression [29].
Although airway clearance with chest physiotherapy is
universally recommended the evidence for beneﬁt is limited.
A Cochrane review demonstrated no improvement in lung
function in patients who had regular multimodality airway
clearance techniques [30]. The beneﬁt to individuals seems
to lie in the reduction of cough frequency and improvement
in quality of life. The technique used does not appear
to have any impact on the outcome, although in patients
with gastroesophageal reﬂux, care should be taken when
instituting techniques that use the head down position. This
is particularly important in young children. There have
been no favourable outcomes, in terms of lung function
parameters, with the use of physiotherapy [31].
In bronchiectasis, the rheological properties of mucus
are abnormal with variation in the rheology depending
on the cause of bronchiectasis. In childhood, postinfective
bronchiectasis mucus is less viscous and more transportable
than that of children with CF [32]. The agents used for
airway clearance are either airway hydrators or mucolytics.
Mucolytic agents reduce mucus viscosity and promote
clearance of secretions. They do this via several mecha-
nisms, which include disruption of disulphide bonds and
liquefying proteins that degrade DNA ﬁlaments and actin.
This modality of treatment is an attractive option in a con-
dition where increased mucus tenacity and viscosity isMediators of Inﬂammation 3
a problem. Recombinant DNAse (rhDNAse) has been used
with excellent results in CF. However, in non-CF bronchiec-
tasis such results are not obtained. In a large multicentre trial
by O’Donnell et al., rhDNAse was found to have detrimental
eﬀects in participants with worsening decline in lung func-
tion [33]. Forced vital capacity (FVC) was reduced by 3.1%
compared to placebo. Patients also suﬀered an increase in
the number of exacerbations in the intervention group. This
ﬁnding is in contradistinction to the beneﬁts documented
in CF. This may have several explanations: ﬁrstly, there are
diﬀerences in rheological properties of mucus in the CF
airway when compared to the non-CF bronchiectatic airway
[32]. Secondly, in CF, the pathology is mostly in the upper
lobes, and the use of mucolytics may facilitate clearance with
gravity, whilst in non-CF bronchiectasis the lower lobes are
aﬀected and this may hamper their eﬀective clearance of
thin secretions against gravity [33, 34]. Due to the harm
demonstrated in this study, there have been no paediatric
studies conducted in the use of rhDNAse. Therefore, the use
of this drug is strongly discouraged in patients with non-CF
bronchiectasis. The use of mucus hydrators like hypertonic
saline and mannitol have been studied. Hypertonic saline
has shown beneﬁt in one small adult study when used
in conjunction with chest physiotherapy [35]. A Cochrane
review and a recent trial of the use of mannitol also have
shown beneﬁt in changing the physical properties of mucus
in fourteen adults with bronchiectasis [36, 37].
Antibiotic therapy forms the cornerstone of bronchiec-
tasis treatment. The use of antibiotics can prevent airway
damage by treating infections, maintain and improve lung
functions, and improve quality of life. Pseudomonas infec-
tion is rare in children with non-CF bronchiectasis [38].
Inhaled antibiotics have been extensively studied in the
context of CF. The use of this strategy has the beneﬁt of
targeted drug delivery, limitation of systemic drug absorp-
tion, and reduction of side eﬀects. The drug doses required
for oral and intravenous antibiotics, to achieve bactericidal
levels in airway secretions, need to be between 10 and
25 times above the mean inhibitory concentration. This,
therefore, renders inhaled therapies a more attractive option
in bronchiectasis. In order to have optimal use of inhaled
drugs, they need to be at a pH above 4.0 and have an
osmolarity between 100–1100mOsmol. Several antibiotics,
including tobramycin, ceftazidime, and gentamycin, have
been studied especially in the context of CF in subjects
colonized with Pseudomonas aeruginosa [39–41]. There is
currently insuﬃcient evidence for the recommendation of
the use of inhaled antibiotics, especially since pseudomonas
colonization is a rare event in non-CF bronchiectasis in
children, although small studies with inhaled tobramycin,
colistin, and aztreonam have suggested beneﬁt [39].
Anti-inﬂammatory drugs like corticosteroids are a nat-
ural candidate in the management of bronchiectasis as they
can play a pivotal role in breaking the cycle of inﬂammation.
The anti-inﬂammatory eﬀects are mediated by a reduction
of inﬂammatory cytokines, inhibition of prostaglandins,
reduction in adhesion molecules, and the inhibition of nitric
oxide in the airway. Regrettably, systemic corticosteroids
Table 1: Types of macrolide antibiotics.
14-member ring macrolides
Erythromycin
Troleandomycin
Clarithromycin
Roxithromycin
15-member ring macrolides Azithromycin
16-member ring macrolides
Josamycin
Spiramycin
Midecamycin
cannot be used long term due to their unfavourable side-
eﬀect proﬁle. Inhaled corticosteroids have been shown in
randomized trials to reduce the number of exacerbations,
reduce sputum volume, and improve quality of life in
bronchiectasis [22, 42, 43]. One randomized trial of eighty-
six adults showed that subjects colonized with Pseudomonas
aeruginosa derived the most beneﬁt from the use of inhaled
corticosteroids [22].
4.Macrolides andBronchiectasis
Macrolide antibiotics are a group of antibiotics that contain
a macrocytic lactone ring with a number of sugar moieties
attached to these rings. Macrolides are further subclassiﬁed
according to the number of lactone rings into the 14-,
15-, and 16-member ring macrolides (Table 1). The oldest
of these drugs is erythromycin. Erythromycin is a 14-
member macrolide, which was ﬁrst isolated by McGiure
and colleagues in 1952 from Streptomyces erythreus found
in soil samples in the Philippines. The other macrolides are
semisynthetic agents.
Azithromycin is an azalides with an added methyl-
substituted nitrogen atom onto the lactone ring to form
the 15-member ring. Clarithromycin is formed by the
methylationofthehydroxylgroupatposition6ofthelactone
ring. These structural modiﬁcations confer azithromycin
and clarithromycin a slightly better side eﬀect proﬁle when
compared to erythromycin. These modiﬁcations reduce
the interaction of these drugs with drugs metabolized by
the cytochrome P450 system. There are also signiﬁcantly
fewer gastrointestinal side eﬀects. Azithromycin and clar-
ithromycinalsohaveafarsuperiortissuepenetrationinvitro
and a longer elimination half life and, thus, need once daily
dosing. The drawback of the use of these agents is their
signiﬁcantly higher cost when compared to erythromycin,
which is a relatively cheap and eﬀective drug. Macrolide
concentrations are at least 10-fold higher in epithelial lung
ﬂ u i dt h a ni ns e r u m[ 44].
Themodeofactionofmacrolidesisbyreversiblebinding
to the 50s subunit of the ribosome in prokaryocytes. This
results in prevention of ribosomal translation and thus pre-
vention of bacterial replication. Macrolides are bacteriostatic
for Staphylococci, Streptococci,a n dHaemophilus, but they
may exert bactericidal eﬀects at very high concentrations.
Macrolides do not have bactericidal eﬀects against Pseu-
domonas aeruginosa but do result in inhibition of bioﬁlm
formation and also inhibit the organism’s ability to produce4 Mediators of Inﬂammation
toxins [45]. Macrolides are commonly used as a ﬁrst-line
therapy for treatment of acute bacterial infections such as
community-acquiredpneumoniainadults.Thepotentialuse
of macrolides for their immune modifying eﬀects was ﬁrst
discovered in patients with severe steroid dependent asthma
[46]. The concomitant use of troleandomycin was found
to result in signiﬁcant improvement in asthma control in
patients and also led to dose reduction of steroids without
loss of asthma control. These immunomodulatory eﬀects of
macrolides are limited to the 14- and 15-membered ring
macrolides.
The use of low-dose macrolides in the management
of chronic inﬂammatory lung disease was initially found
in Japanese patients with diﬀuse panbronchiolitis (DPB)
[47–50]. DPB, a common condition in Japan and South
East Asia, is a progressive inﬂammatory disorder whose
suﬀerers present with chronic productive cough, wheezing,
exertional dyspnoea, chronic sinusitis, mucoid Pseudomonas
aeruginosa colonization, mixed restrictive and obstructive
pulmonary functions, and diﬀuse chronic inﬂammation
involving the bronchiolar and centrilobular regions of the
airway. Untreated, DPB has a very poor prognosis; in 1984,
the ﬁve-year survival rate was 26%. With the use of low
dose erythromycin, the mortality of these patients was
dramatically reduced with 10-year survival rates increasing
to 92% [50]. This was coupled with an improvement
in lung function and quality of life of suﬀerers. The
immunomodulatory eﬀects of macrolides are thought to
resultinreductioninsputumvolume,inhibitionofvirulence
factor production by bacteria, diminished neutrophil inﬂux
and downregulation of IL-8 production, inhibition of NF-κβ
production, and reduction in both ICAM-1 and neutrophil
elastase [51–54]. These immunomodulatory eﬀects result
in a reduction in pulmonary exacerbations, improved lung
function, and improved quality of life [28, 55–61]. The
clinical improvement of subjects may take up to three
months to show an eﬀect.
The use of macrolides is not only limited to DPB. In
the late 1990s, there was rekindled interest in the use of
macrolides in the treatment of other chronic inﬂammatory
lung disorder including CF. CF is a genetic disorder caused
by a defect on chromosome 7, resulting in an abnormal CF
transmembraneregulatorgene,whichresultsinanabnormal
chloride secretion by the apical epithelial cells. The accu-
mulation of aberrant CFTR in the endoplasmic reticulum is
thoughttoresultincalciumreleaseandstimulation ofNFκβ.
NFκβ causes the release of IL-8 and inﬂammation of the
airway. As the inﬂammatory process becomes chronic, there
is histotoxic inﬂammation with an increase of lymphocytes
and monocytes; this process occurs in the CF airway
with continued predominance of neutrophils [62, 63]. It
is thought that the chronic infections that occur in CF
cause an increase in granulocyte colony stimulating factor
(GCSF) and GM-CSF with signalling of reduction in cellular
apoptosis causing this persistence of neutrophillic airway
inﬂammation. In the setting of CF, azithromycin has been
consistently found to result in a reduction in the number
of pulmonary exacerbations, time to ﬁrst exacerbation, and
improvement in nutritional parameters [64–67]. In CF,
macrolides form part of the cornerstone of therapy in sub-
jects colonized with Pseudomonas aeruginosa, with emerging
evidenceoftheirbeneﬁtinCFsubjectswithoutPseudomonas
aeruginosa [68]. With initiation of macrolides, there is a
modest initial improvement in lung functions.
There are a few studies looking at the immunomodula-
tory role of macrolides in the management of patients with
non-CF bronchiectasis (Table 2). One adult study by Tsang
et al. studied the eﬀect of erythromycin in patients with
severe idiopathic bronchiectasis. They found a signiﬁcant
improvement in FEV1, FVC, and sputum volume over
a period of 8 weeks in 11 patients when compared to
10 controls [58]. In this study, there was no change in
the proinﬂammatory mediators (IL-8, TNF-α,I L - 1 αβ,a n d
leukotriene B4). Only one study in children showed an
improvement on the small airways (maximal mid-expiratory
ﬂ o w )a n dar e d u c t i o ni nI L - 8[ 59]. The trials conducted on
macrolides in bronchiectasis are limited in patient numbers
and length of treatment but universally all have shown
a consistent reduction in the frequency of exacerbations and
sputum volumes [28, 57, 59, 60].
5. Macrolide Resistance andSafety
Long-termuseof macrolidesresultsin resistance particularly
to Streptococci, Haemophilus,a n dStaphylococci. There are
three mechanisms by which resistance occurs [69]. Firstly,
this may be due to ribosomal target modiﬁcation mediated
by methylases encoded by the erm(B) gene. The second
mechanism is due to mutation of the 23S rRNA or ribosomal
proteins L4 and L22. This leads to conformational changes
in the binding site of macrolides. Finally, active drug eﬄux
occurs due to the membrane bound eﬄux protein mef(A)
gene. Phaﬀ et al. found increasing resistance of S. aureus
to macrolides in CF patients, with an in resistance of
17.2% in those on macrolides versus 3.6% in CF subjects
not on macrolides [70]. Tramper-Stranders et al. also
found an exponential increase in Staphylococcal resistance
to macrolides with increases from 83% in the ﬁrst year of
therapy to 100% in the third year of macrolide use [71].
There are safety concerns on the long-term use of
macrolides. There is concern of cardiac side-eﬀects (tor-
sades de pointes) when using macrolides, particularly ery-
thromycin,inconjunctionwithdrugsthatinhibittheCYP3A
pathway. Postmarketing surveillance of the long-term use
of erythromycin in Japan indicate this to be extremely rare
[69]. The biggest concern with the use of macrolides is the
development of resistant organisms, particularly the non-
tuberculous mycobacteria (NTM), which are commonly
found in bronchiectasis patients. The newer macrolides
azithromycin and clarithromycin form the backbone therapy
for NTM management. It is known that carriage of NTM
is high in bronchiectasis patients. A multicentre trial of CF
subjects recovered NTM in 13% of over 900 subjects studied
[72]. There is, therefore, a need for the development of
novelmacrolidesthathavenoantimicrobialactivityandonly
immunomodulatory properties.Mediators of Inﬂammation 5
Table 2: A summary of clinical trials of the use of macrolide therapy in bronchiectasis.
Author Year Study drug Study design Age group Beneﬁt
Tsang et al. [58] 1999 Erythromycin RDBPCT Adult
↑ FEV1, ↑ FVC
↓ sputum volume
Yalcin et al. [28] 2006 Clarithromycin RPCT Paediatric
↓ sputum volume,
↓ sputum cytokines
Koh et al. [59] 1997 Roxithromycin RDBPCT Adult
↓ airway reactivity to
methacholine
Davies and Wilson [60] 2004 Azithromycin Prospective open-label Adult
↓ symptoms and
↑ DLCO
Cymbala et al. [57] 2005 Clarithromycin Randomised open-label,
crossover Adult ↓ sputum volume
Serisier and Martin [55] 2011 Erythromycin Retrospective RCT Adult
↓ exacerbations
↓ antibiotic use
Coeman et al. [61] 2011 Erythromycin Retrospective observational Adult Improved symptom
score
Anwar et al. [56] 2008 Azithromycin Retrospective observational Adult
↑ FEV1
↓ exacerbations
Abbreviations: ↑, increased, ↓, decreased; DLCO, pulmonary diﬀusion capacity for carbon monoxide; FVC, forced vital capacity; FEV1, forced expiratory
volume in one second; RCT, randomised controlled trial; RDBCT, randomised double-blind controlled trial; RDBPCT, randomised double-blind placebo-
controlled trial.
6. Conclusion
Macrolides have immunomodulatory properties in addition
to their anti-bacterial eﬀects. The use of macrolides in
non-CF-related bronchiectasis holds great promise as a
therapeutic intervention that will not only aﬀect the quality
of life of suﬀerers but also act on the pathopysiological
mechanism of bronchiectasis. More studies on the use of
macrolides in this condition are needed to further ascertain
their eﬃcacy.
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